Tag: Coronavirus

1. The ChAdOx1 nCov-19 (AstraZeneca) vaccine was not effective for the prevention of mild-to-moderate COVID-19 infection caused by the B.1.351 variant.  2. The ChAdOx1 nCov-19 vaccine was effective against mild-to-moderate non-variant COVID-19 infection after a single injection. Evidence Rating Level: 1 (Excellent)      Study Rundown: With the emergence of COVID-19 variants, there is the...
1. COVID-19 infection during pregnancy was associated with consistent and substantial increases in severe maternal morbidity and mortality and neonatal complications compared to non-infected pregnancies, especially in symptomatic individuals presenting or those with co-morbidities. 2. Women with COVID-19 were at increased risk of severe pregnancy complications including pre-eclampsia/eclampsia, intensive care...
1. Previous infection from SARS-CoV-2 was linked to an 84% lower incidence of reinfection. 2. Median interval between primary infection and reinfection of COVID-19 was greater than 200 days. Evidence Rating Level: 2 (Good) Study Rundown: While it has been suggested that a history of SARS-CoV-2 infection confers protection against subsequent infection,...
1. Patients from a large academic medical center with mild to moderate COVID-19 in receipt of the monoclonal antibody bamlanivimab had a lower 30-day rate of hospitalization. Evidence Level Rating: 2 (Good) Despite the extent to which SARS-CoV-2 has impacted the world and the delivery of medicine and pharmacotherapeutics, remdesivir, an RNA-dependent...
1. ChAdOx1 nCov-19 vaccine has been linked to immune thrombotic thrombocytopenia in patients after vaccination resembling autoimmune heparin-induced thrombocytopenia. 2. Treatment options for this disorder include high-dose intravenous immune globulin and anticoagulants approved for the treatment of heparin-induced thrombocytopenia. Evidence Rating Level: 4 (Below Average)    Study Rundown: Vaccines are the first-line defense...
1. Hospital readmission and all-cause mortality rates are 3.5 and 7.7 times higher in COVID-19 patients after discharge, than the general population. 2. In addition to respiratory illness, COVID-19 patients experienced higher rates of diagnosis of a major adverse cardiovascular event, diabetes, chronic kidney disease, and chronic liver disease. Evidence Rating...
1. Tislelizumab, a monoclonal antibody and PD1/L1 inhibitor, when combined with chemotherapy, showed significantly prolonged progression free survival and higher objective response rate, compared with chemotherapy alone. Evidence Rating Level: 1 (Excellent) Squamous non-small-cell lung cancers (sq-NSCLCs) are often diagnosed at a later stage, leading to poor prognosis and difficult disease management....
1. 80% of patients in the azithromycin plus usual care group reported feeling recovered within 28 days, compared to 77% in the usual care group. 2. Safety outcomes were similar in both groups with 1% of patients reporting hospital admission and no deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Treatments that...
1. Among a large U.S. cohort, previous infection with SARS-CoV-2 appears to confer high levels of immunity against reinfection for at least 8 months. Evidence Level Rating: 2 (Good) As of early March 2021, SARS-CoV-2 has infected nearly 120 million individuals worldwide. The subsequent duration of immunity to reinfection is unknown; infection...
1. 80% of patients in the azithromycin plus usual care group reported feeling recovered within 28 days, compared to 77% in the usual care group. 2. Safety outcomes were similar in both groups with 1% of patients reporting hospital admission and no deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Treatments that...